MBS for weight loss shows greater long-term benefits than GLP-1 medicines
A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo metabolic and bariatric surgery (MBS)...
top of page
Headlines
MBS for weight loss shows greater long-term benefits than GLP-1 medicines
A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo metabolic and bariatric surgery (MBS)...
Research
MBS for weight loss shows greater long-term benefits than GLP-1 medicines
A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo metabolic and bariatric surgery (MBS)...
GLP-1 drugs shown cost-effective for knee osteoarthritis and obesity, but MBS may be the best option from a clinical and economic perspective
A study led by investigators at Mass General Brigham has found that adding semaglutide and tirzepatide to usual care represents a...
Taking semaglutide reduces ‘food noise’
Individuals who are taking semaglutide for weight loss experience less food noise than before, according to research presented at the...
One in five people taking GLP-1s claim food tastes saltier or sweeter than before
Some individuals who are taking Ozempic, Wegovy or Mounjaro find that foods taste sweeter or saltier than before, according to research...
Genetic variants explain why obesity affects people differently
An international team of researchers led by Icahn School of Medicine at Mount Sinai and the University of Copenhagen in Denmark has...
EU approves Novo Nordisk’s oral semaglutide
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to Novo Nordisk’s...
RYGB is effective in men with individualised follow-up protocols
Roux-en-Y gastric bypass (RYGB) is effective in men with obesity, demonstrating substantial excess weight loss and significant long-term...
Weekly dose of semaglutide 7.2 mg can significantly improve weight loss and related health outcomes in adults living with obesity
A higher weekly dose of semaglutide (7.2 mg) can significantly improve weight loss and related health outcomes in adults living with...
Half of people stop taking semaglutide within a year
A population-wide study presented at the Annual Meeting of the European Association for the Study of Diabetes, Vienna, reports that half...
Overweight and obesity do not always increase the risk of an early mortality
The study of tens of thousands of people in Denmark found that those with a BMI in the overweight category, and even some of those living...
Adipokine Hypothesis theorises changes in biology of internal fat may be the leading cause of heart failure
Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person’s internal...
Significant disparities in the availability of MBS services and the level of resident training and exposure
A global survey on general surgery resident involvement in metabolic and bariatric surgery (MBS) has reported that significant...
Industry
All caught up?
New: Directory
Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.
Events
3rd Annual International Symposium on Magnetic Gastrointestinal and Colon Surgery
Tweets
bottom of page